Clinical trials: Hypercholesterolemia
Hypercholesterolemia
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- NCT00677248
- Testing
- Eprotirome and ezetimibe
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karo Bio AB
Hypercholesterolemia
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin
The primary purpose of this placebo-controlled study is to evaluate the low-density lipoprotein cholesterol (LDL-C) efficacy and dose-response of gemcabene 300, 600 and 900 mg/day administered as monotherapy or in combination…
- Trial name
- NCT02591836
- Testing
- Gemcabene, Atorvastatin
- Volunteers
- 277 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Hypercholesterolemia
Lipid-lowering Effect of Plant Stanol Drink
To determine the effect of investigational products on serum LDL cholesterol.
- Trial name
- NCT01716390
- Testing
- Drink that contains plant stanols
- Where
- Sweden
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Raisio Group
Hypercholesterolemia
(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
The primary objective of the study is to demonstrate that the performance of the modified Plasmat® Futura H.E.L.P. Apheresis System is non-inferior to the current FDA approved Plasmat® Secura H.E.L.P Apheresis System for use…
- Trial name
- FUTURA (NCT00526058)
- Testing
- Secura then Futura, Futura then Secura
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- B. Braun Medical Inc.
Primary Hypercholesterolemia
Study to Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia
To Evaluate the Efficacy and Safety of Combination Therapy of AGT and AGZ Versus Monotherapy of AGT in Patients With Primary Hypercholesterolemia.
- Trial name
- NCT05206578
- Testing
- AGT2, AGZ, AGT2, AGT4, AGZ
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypercholesterolemia, Dyslipidemias
Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
This is an open-label extension study of NK-104-306 (NCT00257686) for elderly patients with hypercholesterolemia or combined dyslipidemia.
- Trial name
- NCT00330876
- Testing
- Pitavastatin
- Where
- 59 sites in Denmark, Germany and 3 more
- Volunteers
- 545 people
- Sponsor
- Kowa Research Europe
Hypercholesterolemia
Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.
- Trial name
- NCT00529178
- Testing
- Pravastatin
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
Hypercholesterolemia
Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia (0653-152)(COMPLETED)
To compare the percent (%) change in plasma LDL-C concentration, after a six week course of treatment with ezetimibe 10 mg/day co-administered with an existing statin versus doubling of the existing statin dose
- Trial name
- NCT00652847
- Testing
- ezetimibe, statins
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypercholesterolemia
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25mg and 50mg) co-administered with all approved doses of atorvastatin in a double-blind comparison with placebo, AVE5530 alone and atorvastatin alone in the…
- Trial name
- NCT00741715
- Testing
- AVE5530, atorvastatin
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 1,736 people
- Sponsor
- Sanofi
Homozygous Familial Hypercholesterolemia
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
This study will evaluate the efficacy and safety of zodasiran subcutaneous (sc) injection in participants 12 to <18 years of age with genetically or clinically diagnosed homozygous familial hypercholesterolemia (HoFH) and…
- Trial name
- SPRUCE (NCT07473843)
- Testing
- Zodasiran
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 10 people
- Sponsor
- Arrowhead Pharmaceuticals
Hypercholesterolemia
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing statin treatment in a double-blind manner in comparison with placebo, in the management of patients with primary…
- Trial name
- NCT00729027
- Testing
- 25 mg/day AVE5530, 50 mg/day AVE5530
- Where
- 16 sites in United States, Australia and 14 more
- Volunteers
- 1,015 people
- Sponsor
- Sanofi
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01644188
- Testing
- Alirocumab, Ezetimibe, Lipid Modifying Therapy (LMT)
- Where
- 126 sites in United States, Canada and 8 more
- Volunteers
- 720 people
- Sponsor
- Sanofi
Hypercholesterolemia
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of statin therapy with or without ezetimibe.
- Trial name
- NCT04164888
- Testing
- CIVI 007
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Civi Biopharma, Inc.
Mildly Hypercholesterolemic Subjects
Effect of the Consumption of a Fermented Milk Enriched With Plant Sterols (France)
The purpose of this study is to investigate the effect on cholesterolemia profile of a low fat fermented milk enriched with plant sterol after 3 and 6 weeks of daily consumption in mildly hypercholesterolemic people treated or…
- Trial name
- NCT01574469
- Testing
- 1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test), 2-Low fat fermented dairy product (control)
- Where
- France
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Danone Global Research & Innovation Center
Hyperlipidemias
Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels
The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.
- Trial name
- NCT00813527
- Testing
- Lapaquistat acetate and fenofibrate, Fenofibrate
- Where
- 36 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Takeda
Dyslipidemia
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
- Trial name
- NCT01058083
- Testing
- BMS-770767
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Bristol-Myers Squibb
Hyperlipidemia
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density…
- Trial name
- MENDEL-2 (NCT01763827)
- Testing
- Evolocumab, Ezetimibe
- Where
- 83 sites in United States, Australia and 8 more
- Volunteers
- 615 people
- Sponsor
- Amgen
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemias, High Cholesterol
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of…
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia
- Trial name
- BROADWAY (NCT05142722)
- Testing
- Obicetrapib
- Where
- 181 sites in United States, China and 6 more
- Volunteers
- 2,530 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia, Hypertriglyceridemia
Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia
This study is designed as a pilot study in order to estimate the effect of VAL070-A and VAL070-B products and their variability on LDL cholesterol and lipid metabolism since these data are still unknown for these products and in…
- Trial name
- Lipiback (NCT02989753)
- Testing
- VAL070-A, VAL070-B
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Valbiotis